abstract |
The sterile solution contemplated by the present invention comprises: a salt comprising octreotide in a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide and at least one preservative in a pharmaceutically acceptable carrier, wherein the The sterile solution is present in the injection device. |